Acetoxy Empagliflozin Powder

Product Details

Acetoxy empagliflozin powder is an intermediate in the synthesis of empagliflozin. Empagliflozin, co-developed by Boehringer Ingelheim and Eli Lilly, is a sodium-glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes. At present, it has been sold in the United States, Europe, Japan and other countries.

SGLT-2 inhibitor is a new type of hypoglycemic drug, mainly by inhibiting the expression of SGLT-2, reducing the renal reabsorption of glucose, increasing the excretion of glucose in the urine, thereby reducing the level of plasma glucose, and its hypoglycemic effect is independent of in β-cell function and insulin resistance.

Empagliflozin is used to improve glycemic control in adults with type 2 diabetes who have not achieved adequate glycemic control with diet combined with exercise. It should not be used to treat patients with type 1Chemicalbook diabetes mellitus, patients with elevated blood or urine ketones (diabetic ketoacidosis), patients with severe renal impairment, end-stage renal disease, and patients on dialysis.

Health Benefits

Under the physiological environment, the kidney enters the circulatory system by filtration and reabsorption of glucose to maintain the blood glucose balance in the body, while the glucose enters the blood through the renal tubular lumen, which must be coordinated by the glucose co-transporter. SGLT2 acts as a glucose co-transporter. A form of cotransporter that blocks the reabsorption of glucose in the proximal convoluted tubule, reduces glucose reabsorption in the kidneys, and increases excretion of glucose in the urine, thereby reducing plasma glucose levels. And the hypoglycemic effect does not depend on β-cell function and is not affected by insulin resistance.